Main Catalog

Found 73
Sort by
Webinars
Member Free
Non-Member $30.00
VIEW CART

2019-2020 Pharmaceutical Marketplace Trends

Not Accredited for CPE: This online program will provide an up-to-the-minute analysis of the pharmaceutical market and offer predictions about what lies ahead in the coming months as the health care industry manages the COVID-19 pandemic.
AMCP eLearning Days 2019-2020 Trends
Nexus Conferences
Member Free
Non-Member $30.00
VIEW CART

A Path Forward: Medicaid Accountable Care Organization Implementation

Contact Hours: 1.5. While a dozen states have implemented new Accountable Care Organization (ACO) Medicaid models, another 12 are in the planning phases.
Accountable Care Organization
Nexus Conferences
Member Free
Non-Member $30.00
VIEW CART

A State Medicaid’s Experience Implementing an Oversight Program for Behavioral Health Medications in Publicly Insured Youth

Contact Hours: 1.5. Utilization of behavioral health medications in the pediatric population has increased in recent years, a trend that has generated major concern given the limited supporting evidence.
Patient Care
Home Study Programs
Member Free
Non-Member $30.00
VIEW CART

AMCP Federal and State Legislative/Regulatory Update Home Study 2020

Contact Hours: 1.0. In today’s world, healthcare legislation and regulation move at a staggering pace making it difficult for health professionals to keep up.
Law
AMCP Annual Meeting
Member Free
Non-Member $30.00
VIEW CART

AMCP Headline Session: 2017–2018 Pharmaceutical Marketplace Trends

Not Accredited for CPE: Keeping abreast of industry trends and forecasts is vital to remaining competitive in the evolving managed care arena— especially because market predictions can shape the approach to managing the pharmacy benefit.
AMCP Headline Session 2018
AMCP Annual Meeting
Member Free
Non-Member $30.00
VIEW CART

Best Practices to Implementing Proactive Communications Between Manufacturers and Payers

Contact Hours: 1.25. The recent enactment of the 21st Century Cures Act, and specifically Section 3037 (Cures 3037), modernized provisions of the Food and Drug Administration Modernization Act of 1997, Section 114 (FDAMA 114).
Managed Care Regulation
Nexus Conferences
Member Free
Non-Member $30.00
VIEW CART

Biosimilars in the United States: Barriers, Solutions, Real-World Evidence, and the Experience of One Health System

Contact Hours: 1.5. As of July 2019, the U.S. Food and Drug Administration (FDA) had approved 25 biosimilar or follow-on biologic products.
Biosimilars
AMCP Annual Meeting
Member Free
Non-Member $30.00
VIEW CART

Brand and Generic Drugs in Development

Contact Hours: 1.25. This session focuses on new and emerging brand-name drugs, as well as upcoming generic drug approvals.
Brand and Generic Drugs
Webinars
Member Free
Non-Member $30.00
VIEW CART

Cannabis Use in Health Care: What Payers Need to Know Home Study

Contact Hours: 1 - Despite a lack of regulatory and legal clarity, significant numbers of patients in Medicare, Medicaid, CHIP, and commercial plans currently use medical cannabis.
AMCP eLearning Days Cannabis
Nexus Conferences
Member Free
Non-Member $30.00
VIEW CART

Checking In on Health Care Reform Efforts: What Do They Mean for Payers, Manufacturers, and Patients?

Contact Hours: 1.5. While broader drug pricing reform efforts have taken the lion’s share of attention in health policy discourse over the past year, the Trump Administration has continued to move forward with implementing changes to the Affordable Care Act (ACA).
Health Care Reform